Longeveron Inc. (LGVN) CEO Chris Min on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/14/22
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/12/22
Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022GlobeNewsWire • 08/08/22
Longeveron Announces Abstract Accepted for Presentation at the Alzheimer's Association International Conference (AAIC)GlobeNewsWire • 07/07/22
Longeveron Inc. (LGVN) CEO Geoff Green on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/13/22
Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer's Symposium; International Frailty and Sarcopenia Research ConferenceGlobeNewsWire • 04/14/22
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer's TrialGlobeNewsWire • 04/13/22
5 Short Squeeze Candidates To Watch: Aterian Tops The List, System1 Group And Longeveron Join LeaderboardBenzinga • 04/11/22
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer's Disease in Alzheimer's & Dementia®: The Journal of the Alzheimer's AssociationGlobeNewsWire • 03/31/22
Longeveron Inc. (LGVN) CEO Geoff Green on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/11/22
Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational ProgressGlobeNewsWire • 03/11/22